全球患者来源异种移植模型市场规模、份额、趋势和成长分析报告（2026-2034）

患者来源的异种移植模型市场预计将从 2025 年的 3.3513 亿美元成长到 2034 年的 7.9997 亿美元，2026 年至 2034 年的复合年增长率为 10.15%。

随着製药和生物技术公司专注于个人化医疗，全球患者来源异种移植（PDX）模型市场正稳步成长。 PDX模型是透过将人类肿瘤组织移植到免疫力缺乏小鼠体内而建构的，有助于研究人员更精确地研究癌症行为。全球癌症病例的不断增加以及对有效标靶治疗的需求是推动市场成长的主要因素。此外，对肿瘤学研究和药物研发计画的投入不断增加，也促进了PDX模型的应用。

推动这一市场发展的关键因素之一是对能够忠实再现人类肿瘤生物学的可靠临床前模型的需求日益增长。传统的细胞株模型往往无法准确预测临床结果，而PDX模型则能更好地揭示药物反应。精准医疗倡议的扩展以及学术机构与製药公司之间的合作也促进了这一需求。政府对癌症研究的资助进一步推动了先进研究模型的开发和应用。

未来几年，随着人源化小鼠模型的发展和移植技术的进步，市场预计将持续成长。将基因组分析和生物标记分析整合到PDX平台将进一步提升其在药物研发中的价值。新兴市场医疗保健投资的增加也有望推动市场成长。总而言之，持续创新和对肿瘤学研究的重视将为该市场带来未来的成长机会。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球病患来源异种移植模型市场：依肿瘤类型划分

• 市场分析、洞察与预测
• 肺癌
• 胰臟癌
• 摄护腺癌
• 乳癌
• 其他的

第五章：全球病患来源异种移植模型市场：依模型类型划分

• 市场分析、洞察与预测
• 小鼠模型
• 大鼠模型

第六章：全球病患来源异种移植模型市场：依最终用途划分

• 市场分析、洞察与预测
• 製药和生物製药公司
• 学术研究机构
• CRO 和 CDMO

第七章 全球病人来源异种移植模型市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Charles River Laboratories
  • The Jackson Laboratory
  • Crown Bioscience
  • Altogen Labs
  • Envigo
  • WuXi AppTec
  • Oncodesign
  • Hera Biolabs
  • XenTech
  • Abnova Corp

The Patient-Derived Xenograft Model Market size is expected to reach USD 799.97 Million in 2034 from USD 335.13 Million (2025) growing at a CAGR of 10.15% during 2026-2034.

The Global Patient-Derived Xenograft (PDX) Model Market is growing steadily as pharmaceutical and biotechnology companies focus more on personalized medicine. PDX models are created by implanting human tumor tissues into immunodeficient mice, which helps researchers study cancer behavior more accurately. The rising number of cancer cases worldwide and the demand for effective targeted therapies are major factors supporting market growth. In addition, increasing investment in oncology research and drug discovery programs is boosting the use of PDX models.

One of the key drivers of this market is the growing need for reliable preclinical models that closely replicate human tumor biology. Traditional cell-line models often fail to predict clinical outcomes accurately, whereas PDX models provide better insights into drug response. The expansion of precision medicine initiatives and collaborations between academic institutions and pharmaceutical companies are also contributing to demand. Government funding for cancer research further supports the development and adoption of advanced research models.

In the coming years, the market is expected to expand with advancements in humanized mouse models and improved transplantation techniques. The integration of genomic profiling and biomarker analysis with PDX platforms will enhance their value in drug development. Emerging markets are also likely to witness growth due to increasing healthcare investments. Overall, continuous innovation and strong focus on oncology research will create promising future opportunities for this market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Tumor Type

• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Others

By Model Type

• Mice Model
• Rat Model

By End Use

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• CROs and CDMOs

COMPANIES PROFILED

• Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY TUMOR TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Tumor Type
• 4.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pancreatic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY MODEL TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Model Type
• 5.2. Mice Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Rat Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. CROs and CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Tumor Type
  • 7.2.2 By Model Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Tumor Type
  • 7.3.2 By Model Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Tumor Type
  • 7.4.2 By Model Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Tumor Type
  • 7.5.2 By Model Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Tumor Type
  • 7.6.2 By Model Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PATIENT-DERIVED XENOGRAFT MODEL INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Charles River Laboratories
  • 9.2.2 The Jackson Laboratory
  • 9.2.3 Crown Bioscience
  • 9.2.4 Altogen Labs
  • 9.2.5 Envigo
  • 9.2.6 WuXi AppTec
  • 9.2.7 Oncodesign
  • 9.2.8 Hera Biolabs
  • 9.2.9 XenTech
  • 9.2.10 Abnova Corp